Ri-Yang Liu
Overview
Explore the profile of Ri-Yang Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fan Z, Yang L, Chen Y, Wan W, Zhou D, Mai H, et al.
Ther Adv Hematol
. 2025 Jan;
16():20406207241311774.
PMID: 39781038
Background: Treatment outcomes for acute promyelocytic leukemia (APL) have improved with all-trans-retinoic acid and arsenic trioxide, yet relapse remains a concern, especially in pediatric patients. The prognostic value of minimal...
2.
Huang D, Yang L, Chen Y, Wan W, Zhou D, Mai H, et al.
Blood Cancer J
. 2023 Dec;
13(1):178.
PMID: 38052803
Realgar-Indigo naturalis formula (RIF), an oral traditional Chinese medicine mainly containing Realgar (AsS), is highly effective in treating adult acute promyelocytic leukemia (APL). However, the treatment efficacy and safety of...
3.
Luo J, Zhang X, Huang D, Chen Y, Wan W, Mai H, et al.
Ann Hematol
. 2023 May;
102(7):1713-1721.
PMID: 37199788
Realgar-Indigo naturalis formula (RIF), with AS as a major ingredient, is an oral arsenic used in China to treat pediatric acute promyelocytic leukemia (APL). The efficacy of RIF is similar...
4.
Qiu K, Wang J, Huang L, Li C, Xu L, Liu R, et al.
Am J Hematol
. 2023 Mar;
98(6):869-880.
PMID: 36877527
The efficacy and safety on the addition of vincristine (VCR) and dexamethasone (DEX) pulses to maintenance therapy among childhood acute lymphoblastic leukemia (ALL) remain uncertain. Herein, we perform an open-label,...
5.
Xu L, Geng X, Liao N, Yang L, Mai H, Wan W, et al.
Front Oncol
. 2022 Aug;
12:943761.
PMID: 36033509
Objectives: The prognostic significance of acute lymphoblastic leukemia (ALL) patients with central nervous system leukemia (CNSL) at diagnosis is controversial. We aimed to determine the impact of CNSL at diagnosis...
6.
He Y, Wu X, Zhou D, Yang L, Mai H, Wan W, et al.
Front Oncol
. 2022 Apr;
12:854798.
PMID: 35425700
Objective: Even though childhood acute lymphoblastic leukemia (ALL) has an encouraging survival rate in recent years, some patients are still at risk of relapse or even death. Therefore, we aimed...
7.
Qiu K, Xu H, Luo X, Mai H, Liao N, Yang L, et al.
Front Oncol
. 2022 Jan;
11:797194.
PMID: 34988026
Purpose: To analyzed the outcome of ETV6/RUNX1-positive pediatric acute B lymphoblastic leukemia (B-ALL) with the aim of identifying prognostic value. Method: A total of 2,530 pediatric patients who were diagnosed...
8.
Li X, Li J, Luo X, Wu X, Sun X, Xu H, et al.
BMC Cancer
. 2021 Jan;
21(1):59.
PMID: 33435902
Background: The prognosis of childhood acute lymphoblastic leukemia (ALL) is optimistic with a 5-year event-free survival (EFS) rate of 70-85%. However, the major causes of mortality are chemotherapy toxicity, infection...
9.
Yang M, Wan W, Luo J, Zheng M, Huang K, Yang L, et al.
Am J Hematol
. 2018 Aug;
93(12):1467-1473.
PMID: 30160789
Intravenous arsenic trioxide (ATO) has been adopted as the first-line treatment for acute promyelocytic leukemia (APL). Another arsenic compound named the Realgar-Indigo naturalis formula (RIF), an oral traditional Chinese medicine...
10.
Li C, Liu S, Mai H, Wang Y, Wen F, Liu R, et al.
Zhongguo Dang Dai Er Ke Za Zhi
. 2012 Feb;
14(2):110-3.
PMID: 22357467
Objective: To study the status of iron deposition in patients with β-thalassemia intermedia and major in mainland China. Methods: The status of transfusion and chelation was examined in 39 patients...